-
1 Comment
Morishita Jintan Co., Ltd is currently in a long term downtrend where the price is trading 1.9% below its 200 day moving average.
From a valuation standpoint, the stock is 98.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.9.
Morishita Jintan Co., Ltd's total revenue sank by 1.7% to $2B since the same quarter in the previous year.
Its net income has dropped by 79.8% to $20M since the same quarter in the previous year.
Based on the above factors, Morishita Jintan Co., Ltd gets an overall score of 1/5.
| Industry | Drug Manufacturers - Specialty & Generic |
|---|---|
| Exchange | TSE |
| CurrencyCode | JPY |
| Sector | Healthcare |
| ISIN | JP3924400009 |
| PE Ratio | 21.0 |
|---|---|
| Target Price | None |
| Market Cap | 9B |
| Dividend Yield | 6.2% |
| Beta | -0.1 |
Morishita Jintan Co., Ltd. produces and distributes pharmaceuticals, quasi drugs, medical devices, and food products in Japan. It operates through Healthcare Business and Capsule Business divisions. The Healthcare Business division manufactures and sells Jintan branded products, as well as engages in OEM of dietary supplements, cosmetics, foods, etc. The Capsule Business division is involved in the OEM/ODM of pharmaceuticals, foods, etc., as well as the development of industrial use capsules. Morishita Jintan Co., Ltd. was founded in 1893 and is headquartered in Osaka, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4524.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
